STIPED
Financiado
Transcranial brain stimulation as innovative therapy for chronic pediatric neuro...
Transcranial brain stimulation as innovative therapy for chronic pediatric neuropsychiatric disorder STIPED
Due to lack of targeted interventions, compliance issues, insufficient effect sizes and a high non-responder rate to currently available interventions, there is an urgent need to develop innovative and new interventions for chroni...
Due to lack of targeted interventions, compliance issues, insufficient effect sizes and a high non-responder rate to currently available interventions, there is an urgent need to develop innovative and new interventions for chronic paediatric neuropsychiatric disorders, such as Attention-Deficit/Hyperactivity Disorder (ADHD) and Autism Spectrum Disorder (ASD). Transcranial direct current stimulation (tDCS) has been shown to be an innovative, effective and safe alternative treatment approach for neuropsychiatric disorders in adults. Here, for the first time, the effect of tDCS on core neurocognitive and behavioral outcomes will be proven in children and adolescents. First, effect sizes and safety of standard tDCS in the clinical setting targeting core brain regions and disorder specific cognitive tasks will be established by three phase-IIa randomized, double blind, sham-controlled studies in ADHD and ASD. Second, the impact of brain development and age-dependent anatomical / functional features on effects of tDCS will be studied systematically using methods of modern neurophysiology, neuroimaging and electric current modeling. This involves an additional phase-I clinical trial. Third, mechanisms of tDCS on brain function will be studied, and biomarkers will be developed in order to predict individual response to standard and individualized stimulation protocols. Finally, the applicability of tDCS in children and adolescents will be improved by developing an innovative personalized home-based treatment option in combination with a telemental health service, which will be tested by a fifth, phase-IIa clinical trial. Throughout the entire project, ethical concerns of the target population will be addressed. This project opens a new avenue for the application of tDCS as an alternative treatment for a great number of chronic neuropsychiatric disorders in children and adolescents and will allow flexible integration of tDCS in the daily routine of families.
ver más
Duración del proyecto: 66 meses
Fecha Inicio: 2016-12-09
Fecha Fin: 2022-06-30
Fecha Fin: 2022-06-30
Línea de financiación: concedida
El organismo H2020 notifico la concesión del proyecto el día 2022-06-30
Línea de financiación objetivo
El proyecto se financió a través de la siguiente ayuda:
SC1-PM-09-2016:
New therapies for chronic diseases
Cerrada
hace 8 años
Presupuesto
El presupuesto total del proyecto asciende a
6M€
Líder del proyecto
EVANGELISCHES KLINIKUM BETHEL GGMBH
No se ha especificado una descripción o un objeto social para esta compañía.
Perfil tecnológico
TRL
4-5
Perfil tecnológico
TRL
4-5
378.13K€ |
Participante
1.00K€ |
Participante
743.50€ |
Participante